Compare HITI & VYGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HITI | VYGR |
|---|---|---|
| Founded | 2009 | 2013 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 189.8M | 203.6M |
| IPO Year | 2021 | 2015 |
| Metric | HITI | VYGR |
|---|---|---|
| Price | $2.46 | $3.40 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $6.13 | ★ $16.50 |
| AVG Volume (30 Days) | 394.0K | ★ 507.0K |
| Earning Date | 06-15-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $10,135,000.00 |
| Revenue This Year | $23.73 | $34.04 |
| Revenue Next Year | $12.80 | $7.92 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.02 | $2.94 |
| 52 Week High | $4.06 | $5.55 |
| Indicator | HITI | VYGR |
|---|---|---|
| Relative Strength Index (RSI) | 67.72 | 58.55 |
| Support Level | $2.35 | $3.29 |
| Resistance Level | $2.54 | $4.31 |
| Average True Range (ATR) | 0.08 | 0.14 |
| MACD | 0.02 | 0.04 |
| Stochastic Oscillator | 87.27 | 89.00 |
High Tide Inc is a downstream-focused retailer of cannabis products, distributor, and seller of smoking accessories and cannabis lifestyle products. It is a vertically integrated company in the Canadian cannabis market with various brands in its portfolio such as Canna Cabana, Fastendr, Queen of Bud, Grasscity, Daily High Club, and others. The company's reportable operating segments are: Bricks and mortar, which generates maximum revenue, and E-commerce. Geographically, it derives maximum revenue from its business in Canada, followed by the United States of America, and other international markets.
Voyager Therapeutics Inc is a biotechnology company to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Its pipeline includes programs for Alzheimer's disease, or AD; Friedreich's ataxia, or FA; Parkinson's disease, or PD; and multiple other diseases of the central nervous system, or CNS. Many of its programs are derived from its TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) adeno-associated virus, or AAV, capsid discovery platform, which the company has used to generate novel capsids, or TRACER Capsids, and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous, or IV, dosing. Its segment is developing and commercializing genetic medicine.